Latest Conference Articles

"Older patients lumped in a group are not all the same,” she says.

The type 1 diabetes patients who were continuously administered testosterone treatment showed improvements in glycemic control as well as massive improvements in their weight loss, since testosterone increases lean body mass.

Different chemicals also associated with variations in tumor size and aggression.

Farid Saad, DVM, PhD, Bayer Pharma AG learned that the men with type 1 diabetes did experience benefits of long-term testosterone therapy – they showed improvements in their underlying diseases.

When a patient comes strolling into your office at 4:30 p.m. on a Friday wanting an opioid prescription, that could be a red flag, Suresh Reddy, MD, professor of palliative care at the University of Texas MD Anderson Cancer Center told MD Magazine.

The Affordable Care Act is still under attack, according to the ACP.

The use of the chest x-ray for diagnosing bacterial pneumonia and the role of antibiotics in infected patients have been hot topics in community-acquired pneumonia. Scott Flanders, MD, gave an update at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

Hepatitis C care often doesn't require a specialist.

Physicians can play a role in curbing substance misuse.

NIAID's director announced progress in developing a Zika vaccine.

Diana McNeill, MD, of Duke University Medical Center moderated a panel at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California. The topic of discussion? Personalized care in type 2 diabetes.

Heidi Combs, MD, says that many patients present to the primary care office thinking that they have other health problems when the diagnosis is really anxiety or depression. She discussed the topic at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

Using the database from the 40-country, double-blind phase 3 ARISTOTLE study, which has been around for over 5 years, a sub-analysis was conducted by Renato Lopes, MD, PhD, professor of Medicine at Duke University in Durham, North Carolina and colleagues.

THe ACC's meeting offered studies likelcc200y to impact clinical practice.

In advance of ENDO 2017, the Society announces a detailed new guideline.

It’s a discussion that even the most seasoned physicians might struggle with—when is it time to talk end-of-life care? Ami Bhatt, MD, director of the Adult Congenital Heart Disease Program at Massachusetts General Hospital (MGH) explained both sides of the debate for patients with adult congenital heart disease.

Some women may have suffered with cardiovascular problems since birth while others don’t find out until pregnancy unmasks the condition. Doreen DeFaria Yeh, MD, discusses the importance of merging physicians from cardiology and obstetrics.

Compared with warfarin, are direct oral anticoagulants (DOACs), including apixaban, dabigatran, and rivaroxaban, better at reducing stroke and major bleeding risks in patients with non-valvular atrial fibrillation? Alpesh Amin, MD, professor of medicine at the University of California, Irvine breaks it down at ACC 2017 in Washington, District of Columbia.

Steven Zelenkofske, DO, vice president of US Medical Affairs at AstraZeneca, talked with MD Magazine about the CVD-REAL study where researchers examined patients with type 2 diabetes taking the new class of diabetes drug, SGLT-2 inhibitors. Positive outcomes were reported with dapagliflozin, canagliflozin, and empagliflozin.

Heart damage after non-cardiac surgery is usually missed. A test finds it.

In patients with AFib, digoxin should not be a first-line drug.

Microbleeds in the brain appear to increase with cardiac procedures:Study.

In the first head to head trial, rivaroxaban was more effective than aspirin.

A synthetic version of "good" cholesterol failed to clear blocked arteries.

Bleeding complications with rivaroxaban no worse than with aspirin.

Study: no worries about cognition loss with PCSK9s.

Paul Burton, MD, PhD, revealed results from the phase 3 EINSTEIN CHOICE trial at the 66th Scientific Session of the American College of Cardiology (ACC 2017) in Washington, District of Columbia. The trial examined the use of rivaroxaban (Xarelto/Janssen) or aspirin as extended treatment in patients with VTE.

The Absorb GT1 Bioresorbable Vascular Stent raised concerns at the FDA.

Excitement has been surrounding PCSK9 inhibitors due to high efficacy in lowering cholesterol. However, two reports in 2015 found that two of these drugs (evolocumab and alirocumab) were linked to cognitive issues. A phase 3 trial at ACC 2017 set out to find if that's actually the case.

Drugs were as effective in CTO patients as PCI, Korean study found.